Navigation Links
Prostatic in Medical News

Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms

WALTHAM, Mass., Aug. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2013 to 2018, generic erosion of established agents--most notably tamsulosin--will cause a decline of more than eig...

AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent

PARKERS PRAIRIE, Minn., July 6 /PRNewswire/ -- AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to...

Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients

- Uniquely Selective Agent Offers Significant Improvement - CHICAGO , April 28 /PRNewswire-FirstCall/ -- Data to be presented at the American Urological Association's (AUA) Annual Conference show that RAPAFLO (TM) (silodosin) produces rapid and sustained improvements of both irritati...

Prostate Study Shows BOTOX May Be Safe, Effective Method for Managing Benign Prostatic Hyperplasia

DENVER, April 27 /PRNewswire-USNewswire/ -- Phase II data presented at the annual meeting of the American Urology Association (AUA) indicate that men suffering from an enlarged prostate may benefit from BOTOX(R) injections. The two-stage, multi-center, double-blind, randomized study showed ...

Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)

- RAPAFLO launch anticipated in early 2009 - CORONA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved RAPAFLO(TM) (silodos...

HighPoint Solutions Develops Novel Incentive Compensation Plan for New Benign Prostatic Hyperplasia (BPH) Product

KING OF PRUSSIA, Pa., June 25 /PRNewswire/ -- HighPoint Solutions LLC, a premier provider of business-driven IT solutions, announced today it has been selected to develop an Incentive Compensation Plan for a new Benign Prostatic Hyperplasia (BPH) product currently under FDA approval review. Wi...

AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prosta...

Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs

Long-Term Outlook More Favorable as Drugs from Eli Lilly and GlaxoSmithKline Will Drive the Market in 2016, According to a New Report from Decision Resources WALTHAM, Mass., Sept. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advi...

Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Men's Health Watch

BOSTON, Sept. 5 /PRNewswire-USNewswire/ -- Men with slow urine flow from enlargement of the prostate gland (known as benign prostatic hyperplasia or BPH) should avoid anything that makes the situation worse--and that includes some medications. The most common offenders are over-the-counter col...

Research Finds Lesser Rectal Cancer Risks Associated with Prostatic Irradiation

According to a new study published in the International Journal of Radiation Oncology, no appreciable risks were found to be associated// with prostratic irradiation and the development of rectal cancer. Wayne S. Kendal, M.D., Ph.D., an Associate Professor in Radiation Oncology at the Ottawa Ho...
Prostatic in Medical Technology

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data - CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO (TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produ...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

-- Data Presented at American Urological Association Annual Meeting -- SEATTLE and CHICAGO, April 28 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN ) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small m...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

-- New product, now available in pharmacies, will provide rapid symptom relief for number one reason men visit a urologist -- CORONA, Calif., April 7 /PRNewswire-FirstCall/ --Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that RA...

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

- Innovative pipeline products highlight Watson's commitment to urology - Embargoed Until 2:10 PM EDT ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that investigators p...

Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia

- Data Presented at American Urological Association Annual Meeting - SEATTLE and ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN ) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small...

Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia

CORONA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, today announced that its New Drug Application (NDA) for silodosin, a novel alpha(1)- adrenoreceptor antagonist, has been accepted for filing by the U.S. Foo...

Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced positive results from its newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 26 clinical trial sites across the U.S. and 116 unselected su...

Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases

Additional data to be published in an upcoming issue of Anti-Cancer Drugs VANCOUVER, March 20 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today announced that two peer-reviewed publications will feature Protox's PRX 302. The Journal of the National Cancer Institute ("JNCI") has published th...

Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association

* Ozarelix Effective in Improving Symptoms and Urine Flow, With Long Lasting Effect in Phase 2 Study IRVINE, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc., today announced Phase 2 safety and efficacy data for ozarelix, the Company's drug candidate for the treatment ...

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia

...ng markedly with age. It is often the presenting symptom in men with benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients. There is curren... increasing markedly with age. It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of nocturia...
Prostatic in Medical Products

Cochrane Reviews in Prostatic Diseases and Urologic Cancers

Description: Cochrane Reviews enable all those involved with healthcare decisions to keep up to date with the very latest evidence in their field of interest - a challenge which becomes harder each year as the volume of evidence increases. Cochrane Reviews solve this problem by delivering the best single source...
Company:Skyscape, Inc.

The Spanner Prostatic Stent

Description: The Spanner Prostatic Stent may become a practice-changing technology for the assessment, management, or, perhaps even the treatment of lower urinary tract symptoms (LUTS). Practical applications for The Spanner: Acute retention Men unfit for surgery Waiting list patients Post minim...
Company:AbbeyMoor Medical, Inc.

Acid Phosphatase, Prostatic

Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...
Company:ARUP Laboratories

Total PSA IRMA Test

Description:...irculates bound to anti-chymotrypsin (PSA-ACT) and other compounds. Serum concentrations of PSA are elevated in patients with prostate cancer, benign prostatic hypertrophy (BPH) and prostatitis [1-3]. In addition, PSA serum levels appear to correlate with the volume and clinical stage of prostate cancer [1,4]...
Company:Diagnostic Systems Laboratories, Inc.

PK Plasma V

Description:... V is a single use device that produces rapid, consistent, precise tissue removal with minimal thermal spread and vapor sealing of adjacent tissue for prostatic adenoma in the treatment of BPH, without deep desiccation. Often referred to as PlasmaKinetic vaporization of the prostate (PKVP), the Plasma-V gives ...
Company:GYRUS ACMI

Prolieve™ Thermodilatation System

Description:... minimally invasive therapy for the symptoms of BPH. This dual-action thermodilatation technology simultaneously heats the prostate while dilating the prostatic urethra. The treatment is well tolerated by patients and most patients do not require post-treatment catheterization....
Company:Boston Scientific Corporation

GreenLight PV Laser System

Description:... The GreenLight PV Laser System and PVP (Photoselective Vaporization of the Prostate) Procedure for the Treatment of Benign prostatic Hyperplasia (BPH) allows the urologist to deliver the clinical endpoints of a TURP with the safety and ease of a minimally invasive procedure....
Company:AMS

Coude BARDEX LUBRICATH Latex Foley 2-Way Catheters

Description:... The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffness and radiop...
Company:C. R. Bard, Inc.

Immulite PAP

Description:... Test for prostatic acid phosphatase...
Company:Siemens Medical Solutions Diagnostics

PAP Microwell ELISA

Description:... For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Company:Diagnostic Automation, Inc.
Prostatic in Medical Definition

Patient trade-off

...teineck G. Distress due to unwanted side-effects of prostate cancer treatment is related to impaired well-being (quality of life). Prostate Cancer and prostatic Diseases. 1998: 1:128-133. 3. Helgason ÁR, Dickman PW, Adolfsson J, Steineck G. Emotional isolation : Prevalence and the effect on well-being am...
Prostatic in Medical Dictionary

Urinary hesitancy

...... Urinary hesitancy can be caused by: Benign prostatic hyperplasia ... Treatment of urinary hesitanc...... Urinary hesitancy can be caused by: Benign prostatic hyperplasia ... Treatment of urinary hesitanc...... Urinary hesitancy can be caused by: Benign prostatic hyperplasia ... Treatment of urinary hesitanc...

Urethra

... Anterior urethra drains to superficial and deep ... site of disease in males is bulbomembranous urethra . ... in situ, involvement of the prostatic urethra ... Posterior valve, urethra information including symptoms, diagnosis, misdiagnosis, treatment, causes, patient stories, videos, foru...

Transurethral resection of the prostate

... of the prostate is a urological operation. It is used to treat benign prostatic hyperplasia (BPH). As the name indicates, it is performed by visualisin...rview: For most of the 20th century, from 1909, when Hugh Hampton Young ... prostatic hypertrophy (BPH) was transurethral resection of the prostate (...

Slipped Disc

... symptoms, diagnosis, and ... called a slipped or ruptured) disc is a fragment of the disc nucleus which is ... Presbyopia, Prostate Cancer, prostatic Enlargement, Psoriasis, Rabies, Radiation Exposure Conditions, Raynaud's Disease, Repetitive Stress Syndrome, Reye's Syndrome, ... slipped disk...

Prostate Problems

...e problems including prostatitis and benign prostatic ... Prostate ... the prostate may continue to ...oblems , which include prostate cancer, benign prostatic hyperplasia (BPH), and prostatitis. Here's how t... Prostate Problems Facts and Statistics. Benign prostatic Hypertrophy (BPH) ... Prostate problems ar...

Prostate removal

...of the prostate . ... ... treat an enlarged prostate .See also:Benign prostatic hypertrophyProstate resection - minimally... What is Prostate Removal ?...SA level. ... levels to increase after prostate removal due to benign prostatic ... Prostate removal ... symptoms of an enlarged prostate , althou...

Prostate Disease

...evels two to three times higher ... Urination symptoms suggested Benign prostatic Hyperplasia, it can prevent the ... Warning signs & disease . WARNING ...ee Skene's gland. ... life and is responsible for the disease of benign prostatic enlargement. ... Having a prostate cancer screening test is no guar...

Prostate

...the prostate gland, symptoms, diagnosis, treatment, and postoperative care. Discusses prostate problems including prostatitis and benign prostatic hyperplasia. ... What is prostate enlargement, or BPH? Is BPH a sign of cancer? Is BPH a ... Prostate cancer is diagnosed in an estimated 80...

Hypertrophy

... at LIVESTRONG.COM, the definitive daily health, fitness, and... benign prostatic hypertrophy_BPH, herbal remedies for BPH, causes and symptoms of BPH ... Benign prostatic hypertrophy or BPH - Definition. BPH Causes and Symptoms ... What is ...

Hyperplasia

...within an organ or tissue grow larger and faster than expected. ... If usual ductal hyperplasia is found in your breast biopsy, ... Benign prostatic hyperplasia (BPH) is a condition in which the prostate gland becomes enlarged. ... Hyperplasia is a general medical term referring to excess ....
Prostatic in Biological News

Newly discovered gene fusion may lead to improved prostate cancer diagnosis

...ave benign conditions such as inflammation of the prostate." It is important to distinguish harmful cancer from non-lethal diseases, such as benign prostatic hyperplasia, or enlarged prostate disease that exhibits similar symptoms to prostate cancer, in order to provide effective care, explains Dr. Rubin. G...

Biomarker predicts malignancy potential of HG-PIN lesions in the prostate

... PHILADELPHIA Men whose prostate cancer screenings show high grade prostatic intraepithelial neoplasia (HG-PIN) may find themselves in limbo, stuck between diagnoses they are told prostate cancer has not yet developed, but it ...

University of Minnesota study refutes belief that black men have more aggressive prostate cancer

... men and 1.35 in white men of Gleason score 7 tumors. All these ratios were higher than the average ratio in control tissue taken from men with benign prostatic hyperplasia, a common, noncancerous enlargement of the gland. Sinha said that previous studies had found differences between black men compared to...

Hair-growth drug artificially lowers PSA levels in prostate cancer screening, study finds

...st the PSA interpretation by multiplying it times two for these men." Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients w...
Prostatic in Biological Technology

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an extended study in the Phase 3 program with cetrorelix pamoate for the treatment of benign...

AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia

All amounts are in US dollars QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the signing of a development, commercialization and licensing agreement ...

AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's second efficacy trial of its Phase 3 program in b...

AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia

QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Spectrum Pharmaceuticals (NASDAQ: SPPI ), released Phase 2b results for ozarelix, a ...

AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's first efficacy trial of its Phase 3 program in b...

More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheim's Flomax as First-Line Therapy

Less Than 20 Percent of Patients Diagnosed with the Disease Receive Pharmacotherapy Within a Year of Their Diagnosis, According to a New Report From Decision Resources WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research...

Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia

QUEBEC CITY, March 26 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced with its flagship product candidate, cetrorelix, the Company's lead luteinizing hor...

Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET

...ndreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more informa...

Neurocrine Biosciences Reports Second Quarter 2009 Results

...roduct candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. ne...
Prostatic in Biological Dictionary

Urethra

...e leaves the body. ... One end of the urethra is connected to the bladder. The other ... Learn more about urethra . Also related are Urethra , prostatic urethra , ... In anatomy, the urethra (from Greek οὐρήθρα - ourethra) is a tube which connects ... In anatomy, the urethra is a tube which con...

Prostate gland

...ancer treatment options from the American Academy ... Since the prostate gland and the lymph nodes are not taken out, your doctor ... Benign prostatic hyperplasia is commonly known as an enlarged prostate gland . ... As a result, the prostate gland begins to press on the urethra like a clamp...
Other Tags
(Date:7/9/2014)... OH, July 10, 2014 -- The World Health Organization ... minutes of moderate to vigorous physical activity (MVPA) each ... of their MVPA during school hours. Therefore, it ... hours would increase MVPA. In a new study ... , researchers confirmed that time spent outdoors after school ...
(Date:7/9/2014)... TORONTO, July 10, 2014 For the first time, ... urban Aboriginal population in Canada uses health care. A ... database to clearly demonstrate the unique challenges faced by ... at St. Michael,s Hospital. , The findings, published ... between urban First Nations individuals and the general population. ...
(Date:7/9/2014)... the Perelman School of Medicine at the University of ... have received an $8 million grant from the National ... light therapy (PDT) in patients with malignant pleural mesothelioma, ... manifests itself in the lining of the lungs and ... grant will fund a clinical trial and additional studies ...
(Date:7/9/2014)... A network of signals active in almost all types ... into overdrive, and may help fuel a tumour,s uncontrolled ... of Cancer Research, London, identified a molecular trigger responsible ... the cellular factory that makes the building blocks ... in the TOR signalling pathway, called SREBP, controls the ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2
(Date:7/9/2014)... Jena (Germany) They are amongst the most numerous inhabitants ... Emiliania huxleyi . Not visible to the naked eye, ... square kilometer sized patches, they are even visible on ... is responsible for approximately half of the global ... Friedrich Schiller University Jena (Germany). In the process the ...
(Date:7/9/2014)... they are used in the right ways. ... Hospital and coauthors analyzed six use cases with ... decompensation (when a patient,s condition worsens); adverse events; ... organ systems. They suspect that cost-savings benefits will ... all six scenarios will be significant. The authors ...
(Date:7/8/2014)... LAKE CITY, July 9, 2014 Collectors found the first ... in west Texas. Then, for two decades, the 14-inch-tall plant ... a third. , Now after a long search turned ... Utah botanist and her colleagues identified the spiny plant as ... heart" in Latin because it was found in Valentine, Texas, ...
Breaking Biology News(10 mins):Short circuit in the food web 2The impact of big data on health care: Health Affairs' July issue 2New plant species from the heart of Texas 2New plant species from the heart of Texas 3New plant species from the heart of Texas 4New plant species from the heart of Texas 5
Other Contents